International Clinical Trial: Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)

Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07312292) titled 'Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)' on Dec. 16, 2025.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Niek Wijnen

Condition: Liver Cancer (Locally Advanced or Metastatic) Liver Cancer Adult

Intervention: Drug: Angiotensin II (Giapreza(R))

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: January 1, 2026

Target Sample Size: 15

Countries of Recruitment: Netherlands

To know more, visit https://c...